Longeveron, Inc.

As of August 14, 2024, Longeveron, Inc. is rated as risky due to its overvaluation and poor financial metrics, including a negative ROCE of -508.69%, a year-to-date return of -55.49% compared to the S&P 500's gain of 12.22%, indicating significant deterioration in its investment appeal.

As of August 14, 2024, Longeveron, Inc. is considered overvalued and rated as "risky" due to negative financial metrics, including a P/E ratio that is not applicable, a Price to Book Value of 1.08, a concerning EV to EBITDA of -0.29, and significantly low ROCE and ROE, alongside a year-to-date stock return of -33.53%.

As of June 9, 2025, Longeveron, Inc. exhibits a mildly bearish trend, with mixed indicators showing some bullish signals from the MACD but overall bearish sentiment from moving averages and Bollinger Bands.

Longeveron, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $0 million and a net loss of $5 million as of March 2025. It has a market cap of $18.31 million and key metrics indicating significant financial challenges.

As of Jun 18, Longeveron, Inc. has a market capitalization of 18.31 million, with net sales of 2.22 million and a net profit of -16.92 million over the last four quarters. The company's shareholder's funds are 21.89 million, and total assets are 25.56 million.